Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Evommune, Inc.NYSE: EVMN
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt turns negative
Q1 FY2026 net debt was -$39.2M, compared with $187.25M a year earlier.
Context
- Net debt amounted to 12.2% of total assets at the end of Q1 FY2026, down 322.1 pp from a year earlier.
- Net debt increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -120.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (42M) USD
- Year-over-year change
- -123.7%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (42M) | -123.7% |
| FY2024 | 2024-12-31 | 177.06M | +45.6% |
| FY2023 | 2023-12-31 | 121.61M | — |
Net Debt vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 net debt of -$39.2M is the 9th highest of the 10 companies compared; the peer median is $35.91M.
- Its year-over-year change of -120.9% is the 9th highest of 10, against a peer median of +5.9%.
- Net debt amounts to 12.2% of total assets for EVMN, versus a peer median of 19.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $948.9M | -18.2% | — | 35.0% |
| Sep 2026 | $562.25M | +1324.1% | — | 47.8% | |
| Mar 2026 | $140.02M | -5.3% | +58.0% | 106.5% | |
| Jun 2026 | $124.75M | +301.4% | +86.3% | 5.7% | |
| Mar 2026 | $35.91M | -12.8% | — | 27.8% | |
CLYMClimb Bio, Inc. | Mar 2026 | -$7.88M | +72.4% | — | 5.2% |
| Mar 2026 | -$9.38M | -180.9% | — | 3.2% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | -$10.69M | +34.8% | — | 10.1% |
EVMNEvommune, Inc. | Mar 2026 | -$39.2M | -120.9% | — | 12.2% |
| Mar 2026 | -$57.48M | +5.9% | — | 19.9% | |
| Peer median (excluding EVMN) | $35.91M | +5.9% | +72.2% | 19.9% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.